{
    "clinical_study": {
        "@rank": "136032", 
        "arm_group": {
            "arm_group_label": "No treatment", 
            "description": "Observation"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the long term safety and preliminary efficacy of\n      intramedullary transplantation of HuCNS-SC cells in subjects with thoracic spinal cord\n      trauma."
        }, 
        "brief_title": "Long-Term Follow-Up of Transplanted Human Central Nervous System Stem Cells (HuCNS-SC) in Spinal Cord Trauma Subjects", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Retinitis Pigmentosa", 
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigation is a multi-year observational study following the completion of the\n      open-label, single dose Phase I/II study involving transplantation of allogeneic HuCNS-SC\n      cells into 12 subjects with thoracic spinal cord injury.\n\n      Subjects will be monitored at routine intervals for safety and preliminary efficacy for four\n      years. The LTFU study will commence following the one year post-transplantation termination\n      visit of the Phase I/II investigation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have undergone HuCNS-SC transplantation as a subject in the Phase I/II trial\n\n          -  Must agree to comply in good faith with all conditions of the study and to attend all\n             required study visits\n\n        Exclusion Criteria:\n\n          -  Subjects have received or are receiving off-protocol immunosuppressive medications\n\n          -  Subjects who, after completion of Phase I/II trial (Protocol # CL-N02-SC), have\n             entered or are about to enter any other investigational study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who had undergone intramedullary transplantation of HuCNS-SC cells in the\n        thoracic region."
            }
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725880", 
            "org_study_id": "CL-N03-SC", 
            "secondary_id": "TpP_I_2012_002"
        }, 
        "intervention": {
            "arm_group_label": "No treatment", 
            "intervention_name": "Observation", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Spinal Cord Injury", 
            "HuCNS-SC cells", 
            "Human Neural Stem Cells", 
            "Neural Stem Cells", 
            "Stem Cells"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "link": {
            "description": "Spinal Cord Injury Trial", 
            "url": "http://www.stemcellsinc.com/Therapeutic-Programs/Spinal-Cord-Injury.htm"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "zip": "8008"
                }, 
                "name": "Uniklinik Balgrist"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Long-term Follow-up (LTFU) Study of the Phase I/II Safety and Preliminary Efficacy Investigation of Intramedullary Spinal Cord Transplantation of HuCNS-SC\u00ae in Subjects With Thoracic (T2-T11) Spinal Cord Trauma", 
        "overall_official": {
            "affiliation": "StemCells, Inc.", 
            "last_name": "Stephen Huhn, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evidence of improvement in ASIA impairment scale as confirmed by neurological examination", 
            "measure": "American Spinal Injury Association (ASIA) Impairment Scale Improvement", 
            "safety_issue": "No", 
            "time_frame": "Four years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725880"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "StemCells, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "StemCells, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}